Appendix 4D and Half Year Report
Filed with ASX · · 22 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenue from continuing operations compared to the previous year, while total operating losses also rose. The company did not declare any dividends during this period, and it experienced a loss attributable to its owners, reflecting ongoing restructuring efforts. The report highlights the acquisition of FMG, which contributed positively to revenue, despite challenges in other areas of the business.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Anagenics
- Investor Presentation
- Completion of Placement
- Appendix 4C and Quarterly Activity Report
- Business Update
- Acquisition of Face MediGroup Presentation
Later from Anagenics
- H1 FY24 Results and Corporate Update
- Organisational Changes
- Quarterly Activities/Appendix 4C Cash Flow Report
- Midkine Antibody Licensing Deal
- Appendix 4C Cash Flow & Activities Report
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics